Patients With Stage III-IVa Nasopharyngeal Carcinoma With or Without a Mobile Medical Platform Full-course Nutritional Intervention

Inclusion criteria

• 1.Voluntarily participate and sign the informed consent in writing.
• 2.Stage III-IVa (AJCC 8th edition staging) .
• 3.Received induction chemotherapy + concurrent chemoradiotherapy .
• 4.18-70 years old.
• 5.Pathologically diagnosed with non-keratinizing nasopharyngeal carcinoma (differentiated or undifferentiated, that is, WHO type II or III).
• 6.No previous anti-tumor therapy .
• 7.ECOG score 0-1.
• 8.Ensure contraception during the study period.
• 9.Hemoglobin (HGB) ≥90 g/L, white blood cell (WBC) ≥4×109/L, platelet (PLT) ≥100×109/L.
• 10. Liver function: ALT, AST < 2.5 times the upper limit of normal (ULN), total bilirubin < 2.0 × ULN.
• 11. Renal function: serum creatinine <1.5×ULN.
• 12.Able and willing to use a mobile phone or tablet to fill in the electronic scale.

Exclusion criteria

• 1.Received antitumor therapy in the past.
• 2. The pathology was keratinizing squamous cell carcinoma (WHO type I).
• 3.Pregnant women who are in the reproductive period and have not taken effective contraceptive measures.
• 4. Has suffered from other malignant tumors (except for cured basal cell carcinoma or carcinoma in situ of the cervix).
• 5.Patients with significantly low heart, liver, lung, kidney and bone marrow functions.
• 6.Serious, uncontrolled medical diseases and infections.
• 7.Concurrent use of other experimental drugs or other clinical trials.
• 8. Refused or unable to sign the informed consent to participate in the trial.
• 9.Those who have other contraindications to treatment.
• 10.Persons with personality or mental disorders, no capacity for civil conduct or limited capacity for civil conduct.